Summary of Lothian Joint Formulary Amendments

The purpose of this summary is to detail the main changes to the LJF sections and provide additional information on the reasons for some of the changes. The website chapters should be referred to for full details. The month indicates when Formulary Committee approved the changes.

April 2016

### Chapter 1 Gastrointestinal – Adults

1.2 antispasmodics
- The dosing information for metoclopramide has been updated.

1.3 **H Pylori eradication.**
- The recommendation for second line treatment following eradication failure has been changed. DeNol is no longer available, therefore the treatment regimen had to be changed.

### Chapter 4 Central Nervous System – Adults

4.6 (a) **drug treatment of nausea and vomiting**
- The dosing information for metoclopramide has been updated.

4.11 **drugs for dementia**
- Reference to the shared care agreements has been removed. GPPC and HSSMC have agreed that there is no longer a requirement for shared care documents to support the prescribing of dementia drugs.

### Chapter 6 Endocrine – Adults

6.1 **Drugs used in diabetes**
6.1.6 **diagnostic and monitoring agents for diabetes mellitus**
(a) **capillary blood glucose monitoring**
- Blood glucose meters for use in patients with type 2 diabetes were reviewed.
- First and second choice of testing strips and meters have been changed.
- There is now no difference in meter/strip choice for those type 2 patients who are treated with insulin or without.
- The new strips are also a much more cost effective option.
**General Notes**
The main aims of this review have been to update the information in the paediatric section and to bring consistency to the adult and paediatric sections where appropriate. Dosing information is in line with the current BNF/BNFc. The prescribing notes have been expanded to explain the process of treatment selection and some of the factors considered in tailoring of treatment to the individual patient.

**Adults section 4.4 (b)**
- The licensed preparation of lisdexamfetamine mesilate for adults is specified (**Elvanse Adult®**)
- A reminder has been included to prescribe modified release methylphenidate preparations by brand. The pharmacokinetic profiles of brands differ.
- Atomoxetine liquid has been included. Prescribing is restricted to patients who are unable to swallow capsules.

**Paediatrics section 4.12(a)**
- Atomoxetine and lisdexamfetamine mesilate (**Elvanse®**) have been added as second choices.
- Dexamfetamine remains a second choice option for paediatric patients to allow for flexible dosing according to routines (e.g. bedtime).
- A reminder has been included to prescribe modified release methylphenidate preparations by brand.
- Prescribing note which recommended prescribing dexamfetamine first line in patients with epilepsy has been deleted. This is no longer recommended in practice.
- The prescribing note for patient’s with ADHD symptoms who have other co-morbid conditions has been amended to include a wider range of neurological and neurodevelopmental disorders.
- Guanfacine modified release has been added as a prescribing note.

---

**10.1.3 Biologics**
- The section has been updated to note that the biosimilar brands of choice for etanercept and infliximab are Benepali® and Remsima® respectively.
- First choice biologic is now Benepali® rather than certolizumab.
6.5.2 Posterior pituitary hormones and antagonists (a) diabetes insipidus

- Information has been added to note the importance of ensuring doses of desmopression are not omitted. This follows patient safety advice issued by NHS England.

9.5.1.1 Calcium supplements

- Calcium preparations that are no longer available have been deleted.

Dental Formulary

- The Dental Formulary section of the LJF links to 'Drug Prescribing for Dentistry’ guidance, produced by the Scottish Dental Clinical Effectiveness Programme
- The guidance was updated in January 2016.